Parvus Therapeutics Revenue and Competitors

Parvus is pioneering an innovative class of disease-modifying therapeutics - Navacims™ - with best-in-disease potential. Current treatment approaches to autoimmune disease generally require suppression of the immune system to prevent immune attack against a patient's own tissues. In contrast, Navacims represent a paradigm shift in treatment approach wherein the immune system is restored to a balanced ‘response ready' and immune self-tolerant state thru the induction and abundant systemic expansion of disease-specific type 1 regulatory T (TR1) cells. Parvus has demonstrated disease reversal with Navacims in multiple in vivo disease models. Two programs are advancing toward the clinic, the first targeting type 1 diabetes (partnered with Novartis) and the second targeting primary biliary cholangitis (PBC), a progressive disease characterized by chronic inflammation, scarring, and destruction of the bile ducts leading eventually to liver failure.